Streetbeat News

DTCFF

Defence Therapeutics Inc

Industry

Research and Development in Biotechnology

Open

1.00

Mkt cap

55M

Volume

900

High

1.00

P/E Ratio

-16.61

52-wk high

1.30

Low

1.00

Div yield

N/A

52-wk low

0.27

Defence Therapeutics Inc. has successfully closed the second tranche of its non-brokered private placement, raising a total of $4.2 million. The offering was fully subscribed, with each unit priced at $0.60, consisting of one common share and one warrant.

Portfolio Pulse from

January 31, 2025 | 11:15 pm

Defence Therapeutics Inc., a Canadian biopharmaceutical company, has strengthened its patent portfolio with new issuances and allowances in multiple jurisdictions. This development is based on their discovery of enhanced efficacy and stability in Accum® variant multimers.

Portfolio Pulse from

January 06, 2025 | 8:30 am

Defence Therapeutics Inc., a Canadian biopharmaceutical company, announced a non-brokered private placement to raise up to $4.2 million. The offering includes up to seven million units at $0.60 per unit, each consisting of one common share and one warrant.

Portfolio Pulse from

December 31, 2024 | 9:45 pm

Defence Therapeutics Inc., a Canadian biopharmaceutical company, has announced the appointment of Dr. Elias Theodorou to its board of directors. Dr. Theodorou is an expert in molecular and antibody research, which aligns with Defence's focus on developing radiopharmaceuticals and ADC products.

Portfolio Pulse from

December 20, 2024 | 8:30 am

Defence Therapeutics Inc., a Canadian biopharmaceutical company, is set to hold its annual general and special meeting of shareholders on December 12, 2024. The company is involved in developing radiopharmaceuticals, ADC products, and immune-oncology vaccines.

Portfolio Pulse from

December 03, 2024 | 12:15 am

Defence Therapeutics Inc., a Canadian biopharmaceutical company, has appointed Dr. Maxime Parisotto as Chief Scientific Officer and Director of Science and Business Development. Dr. Parisotto brings over 20 years of experience in biochemistry, drug development, and innovation to the company.

Portfolio Pulse from

November 25, 2024 | 8:30 am

Defence Therapeutics Inc. announces a new offering of unsecured convertible debentures to settle outstanding debt, aiming to raise up to CAD$1,570,000. The debentures bear an 8% interest rate and mature in November 2025.

Portfolio Pulse from

November 15, 2024 | 12:45 am

Defence Therapeutics Inc., a Canadian biopharmaceutical company, has announced the appointment of Dr. Svetlana Selivanova, an expert in radiopharmaceuticals, to its board of directors. This move is expected to enhance the company's expertise in developing radiopharmaceuticals and ADC products.

Portfolio Pulse from

November 13, 2024 | 8:30 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.